New combo therapy targets advanced lung cancer in early trial
NCT ID NCT02839265
First seen Apr 29, 2026 · Last updated Jun 10, 2026 · Updated 8 times
Summary
This study tested a new treatment for people with advanced non-small cell lung cancer that had gotten worse after standard treatments. The treatment combined a daily injection of an immune-boosting drug (FLT3 ligand) with targeted radiation to one tumor. The goal was to see if this approach could help control the cancer for at least 4 months. The study involved 33 participants and was completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
Conditions
Explore the condition pages connected to this study.